2608

a

MW x10-3 PBS
200-

200-
PDGF-BB 50 ng/ml
B16/mock clone
B16/PDGF-BB clone
PBS
HASUMI ET AL.
B16/PDGF-BB clone
PDGF-BB 0.1 ng/ml
PDGF-BB 5 ng/ml
b
107,
106.
IB: pTyr
105
IB: PDGFRB
104
0
2
4
6 8
Time (days)
C
vehicle (n=8)
-vehicle (n=7)
STI571 (n=8)
-STI571 (n=6)
500
500
PTK787 (n=7)
PTK787 (n=5)
400
PTK787/ST1571 (n=7)
400
PTK787/ST1571 (n=9)
300
300
200
6565
200
*§#
100
100
0
0
0
24
2 4
6 8 10 12
Time (days)
14
0
2
4
6
8
10
Time (days)
e
STI
STI
STI
MW x10-3
C Veh PTK PTK 100
200
250
IB:pTyr
150
250
IB: PDGFRB
150
1 1.3 0.6 0.2 1.4 0.9 0.1 0.6 0.1 0.1
1.15 0.40 1.15 0.35 0.10
Relative phosph.
Mean relative phosph.

FIGURE 1 Combination of VEGFR and PDGFR tyrosine kinase inhibitors inhibits B16 melanoma tumor growth *in vivo*. (*a*) Subconfluent
cultures of PAE/PDGFR\( \beta \) cells were stimulated with conditioned media from B16/mock or B16/PDGF-BB cells for 1 hr on ice (left panels).
Alternatively, PAE/PDGFR\( \beta \) cells were incubated for 5 min at 37°C with conditioned medium or increasing amounts of PDGF-BB (right pan-
els). PDGFR\( \beta \) phosphorylation was analyzed by PDGFR\( \beta \) and phospho-tyrosine (pTyr) immunoblotting of wheat germ agglutinin adsorbed
fractions of cell lysates. (*b*) B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle (\( \Diamond \)), 3 \( \mu \)M ST1571 (■), 1
\( \mu \)M PTK787 (▲) or 3 \( \mu \)M ST1571 and 1 \( \mu \)M PTK787 (). B16/mock (*c*) or B16/PDGF-BB (*d*) cells were inoculated subcutaneously to C57B16/J
mice. When the tumor volume reached 20 mm\( ^3 \), mice received either p.o. gavage of vehicle (\( \Diamond \)), 100 mg/kg/day STI571 (■), 25 mg/kg/day
PTK787 (▲) or 100 mg/kg/day STI571 and 25 mg/kg/day PTK787 (O). Treatment was given for 13 days for mice bearing B16/mock tumors (*c*)
and 8 days for mice bearing B16/PDGF-BB tumors (*d*). Tumor volumes, determined by palpation were followed over time. Results are presented
as mean and S.E.M. Statistical significance was evaluated using a one-way ANOVA followed by *post hoc* analysis applying the Duncan adjust-
ment. Significance is shown for the last day of treatment: *, *p* < 0.05 compared to vehicle treatment; §, *p* < 0.05 compared to PTK787 treat-
ment; #, *p* < 0.05 compared to STI571 treatment. (*e*) Sis-NIH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/STI571
(25 mg/100 mg/kg/day; lanes 4 and 5), PTK787 (25 mg/kg/day, lanes 6 and 7), STI571 (100 mg/kg/day, lanes 8 and 9) or STI571 (200 mg/kg/
day, lanes 10 and 11). PDGFR\( \beta \) was immunoprecipitated from 15 mg tumor lysate, and receptor phosphorylation was analyzed by PDGFR\( \beta \)
and phospho-tyrosine (pTyr) immunoblotting. Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1).
The ratio between the densitometric analysis of the phosphotyrosine band and the upper, mature PDGFR\( \beta \) band were compared to the first vehi-
cle-treated tumor to obtain the relative receptor phosphorylation.

Results
*In vitro* characterization of a *B16F10* melanoma clone
which produces PDGF-BB

A B16 melanoma cell line producing PDGF-BB (B16/PDGF-
BB) was previously established. \( ^{26} \) This cell line was used to iso-
late a clone with robust PDGF-BB production that was selected
for further experiments. As shown in Figure 1*a* (left panels), con-
ditioned medium from the selected B16/PDGF-BB clone, but not
from a mock-transfected clone (B16/mock), induced strong
PDGFRB phosphorylation in porcine aortic endothelial cells
transfected with the PDGFR\( \beta \) (PAE/PDGFR\( \beta \)), indicating pro-
duction of a large amount of PDGF-BB. The amount of PDGF-
BB released into the conditioned medium was estimated by incu-
bating PAE/PDGFR\( \beta \) cells with either conditioned medium or
increasing amounts of PDGF-BB. After 2 days, the B16/PDGF-
BB cells had released an amount of PDGF into the medium that
was in excess of 0.5 ng/ml PDGF-BB (Fig. 1*a*, right panels). It
should be noted that PDGF-BB sticks to both cells and plastic, so
this amount is likely to represent underestimation of the produc-
tion of PDGF-BB.
